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Regulation of viral genome expression is the result of
complex cooperation between viral proteins and host
cell factors. We report here the characterization of a
novel cellular factor sharing homology with the specific
cysteine-rich C-terminal domain of the basic helix-loop-
helix repressor protein I-mfa. The synthesis of this new
factor, called HIC for Human I-mfa domain-Containing
protein, is controlled at the translational level by two
different codons, an ATG and an upstream non-ATG
translational initiator, allowing the production of two
protein isoforms, p32 and p40, respectively. We show
that the HIC protein isoforms present different subcel-
lular localizations, p32 being mainly distributed
throughout the cytoplasm, whereas p40 is targeted to
the nucleolus. Moreover, in trying to understand the
function of HIC, we have found that both isoforms stim-
ulate in T-cells the expression of a luciferase reporter
gene driven by the human T-cell leukemia virus type
I-long terminal repeat in the presence of the viral trans-
activator Tax. We demonstrate by mutagenesis that the
I-mfa-like domain of HIC is involved in this regulation.
Finally, we also show that HIC is able to down-regulate
the luciferase expression from the human immunodefi-
ciency virus type 1-long terminal repeat induced by the
viral transactivator Tat. From these results, we propose
that HIC and I-mfa represent two members of a new
family of proteins regulating gene expression and char-
acterized by a particular cysteine-rich C-terminal
domain.
Human T-cell leukemia virus type I (HTLV-I)1 and human
immunodeficiency virus type 1 (HIV-1) are both human retro-
viruses that infect in vivo CD41 T lymphocytes. However, these
infections lead to two extremely different diseases. Infection
with HTLV-I results in dysregulation of T-cell proliferation,
sometimes causing the development of adult T-cell leukemia.
By contrast, infection with HIV-1 causes the loss of T-cells,
resulting in systemic immunosuppression and development of
AIDS. Characterization of molecular mechanisms involved in
the interactions between viral and cellular components contrib-
utes to understanding why HTLV-I and HIV-1 have different
effects on the infected T-cell growth. For instance, the tran-
scriptional regulators used by T-cells to control cell function are
used differently by HTLV-I and HIV-1 to regulate expression of
their genome. Both retroviruses utilize the cellular RNA po-
lymerase II to transcribe their genome (1–4) but also code for
their own regulatory proteins that regulate the transcription of
viral and cellular genes. Thus, HIV-1 Tat protein is able to
activate transcription from the viral long terminal repeat
(LTR) promoter (5–7) by interacting with the transactivation
responsive element located at the 59 end of viral mRNAs (8–10)
and then with general transcription factors (for reviews see
Refs. 11 and 12). By contrast, HTLV-I Tax protein is unable to
bind specifically to nucleic acids (13–15). To stimulate tran-
scription from LTR promoter, Tax is recruited by interaction
with the activating transcription factors/CRE-binding proteins
(ATF/CREB) (16–20) that bind to the three imperfect 21-bp
cAMP-responsive elements located in the U3 of the LTR (21–
25). Then, Tax could stimulate transcription by recruiting the
coactivator CREB-binding protein (CBP) (26–28) and by inter-
acting with basal transcription factors (29–31).
Basic helix-loop-helix (bHLH) proteins regulate cell determi-
nation and differentiation during embryogenesis (for reviews
see Refs. 32 and 33). For example, the cell fate of skeletal
muscle precursors is regulated by the MyoD subfamily of bHLH
factors including MyoD, Myf5, myogenin, and MRF4 (33, 34).
bHLH proteins are also involved in lineage commitment and
differentiation as Mash2 and Hand1, which play a role in
trophoblast development (35–37). The activity of bHLH factors
is regulated to achieve the coordinated expression of genes
during development. Recently, a novel myogenic repressor has
been identified called I-mfa for Inhibitor of MyoD family (38,
39). I-mfa is generated with two additional proteins, I-mfb and
I-mfc, by alternative splicing (38). The three I-mf proteins
share a common N-terminal region, but each has a different C
terminus, the I-mfa-specific C terminus being characterized by
a high content of cysteines. I-mfa is distributed mainly
throughout the cytoplasm, although it is also detectable in the
nucleus (38). I-mfa inhibits myogenic bHLH proteins by retain-
ing them in the cytoplasm and by interfering with their DNA
binding activity in the nucleus (38). I-mfa is also able to inhibit
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the transactivation activity of Mash2 and plays an important
role in trophoblast and chondrogenic differentiation (39). On
the other hand, the functions of I-mfb and I-mfc still remain
unclear.
In this study, we report the isolation and characterization of
a human cDNA clone encoding a novel protein, which exists in
two isoforms differing by the presence or absence of a basic
amino acid-rich N-terminal domain and by their localization in
the cell. Both isoforms contain a common C terminus sharing
homology with the specific C-terminal domain of I-mfa. We
show that this new factor, called HIC for human I-mfa domain-
containing protein, stimulates the expression of a luciferase
reporter gene driven by the HTLV-I LTR in the presence of
Tax. By using mutagenesis, we demonstrate that the I-mfa-like
domain of HIC is required to stimulate luciferase expression.
Finally, we also show that HIC is able to down-regulate expres-
sion from HIV-1 LTR in the presence of Tat. From these re-
sults, we propose that HIC and I-mfa represent a new family of
proteins regulating gene expression and are characterized by
the presence of a specific cysteine-rich C-terminal domain. Our
results also suggest that HIC could differently regulate expres-
sion of HTLV-I and HIV-1 genomes.
EXPERIMENTAL PROCEDURES
Molecular Cloning of a 4,152-bp Full-length HIC cDNA—HIC cDNA
clones were first isolated from a MT-2 cDNA library by the yeast
two-hybrid approach. MT-2 cDNA fused to the GAL4 activation domain
of the pGAD10 vector (20) was screened by using the cytoplasmic tail of
CD4 as a bait fused to the LEXA DNA binding domain of the pBTM116
vector. The two-hybrid screen was performed as already described (20)
with the Saccharomyces cerevisiae L40 reporter strain.
The multiple tissue Northern blot and the human spleen cDNA
library cloned into lgt11 were purchased from CLONTECH. RNA hy-
bridization and library screening were performed as described by the
manufacturer. The HIC cDNA encompassing the nucleotides from po-
sition 1148 to 1639 was labeled with [a-32P]dCTP using the method of
random priming and was used as a probe.
In Vitro Transcription and Translation—All the different HIC
cDNAs cloned into pSPORT 1 (Life Technologies, Inc.) were transcribed
and translated in the presence of [35S]methionine and [35S]cysteine by
using the TNT T7 coupled transcription-translation reticulocyte lysate
system of Promega. Translation products were analyzed by SDS-PAGE
and autoradiography. pHIC-1 corresponds to an SalI-SpeI fragment
that contains the first 1532 bp of the HIC cDNA subcloned into pSPORT
1. The 59-deleted plasmids, pHIC-2, -3, -4, and -5, were either con-
structed by restriction endonuclease digestion and religation of pHIC-1
or generated by PCR amplification on pHIC-1 and subcloned into
pSPORT 1. Templates where CTG or GTG were mutated were also
generated by PCR amplification; CTG at position 246 was transformed
into ATG (pHIC-I-atg) or CGG (pHIC-I-cgg), GTG at position 264 into
ATG (pHIC-II-atg) or CGG (pHIC-II-cgg), and CTG at position 321 into
ATG (pHIC-III-atg).
Expression of HIC p32 and p40 Tagged with Either GFP or myc
Epitope in COS7 Cells—To express HIC p32 and p40 with a GFP or myc
tag, the complete coding sequences of both proteins were subcloned into
the vectors pEGFP-N1 (CLONTECH), pEGFP-C1 (CLONTECH), and
pcDNA3.1(2)/Myc-His (Invitrogen). We also cloned an NheI-KpnI frag-
ment of HIC cDNA (from position 95 to 1328) into pEGFP-N1 to analyze
the production of HIC protein isoforms in vivo from the wild type leader.
COS7 cells were transfected using the calcium phosphate-mediated
transfection method with 20 mg of expression vector. Cells were culti-
vated on the glass slides and then analyzed by fluorescence 24 h after
transfection. p32 and p40 tagged with the myc epitope were detected by
using the anti-myc monoclonal antibody purchased from Sigma and
goat anti-mouse immunoglobin G antibody coupled to fluorescein iso-
thiocyanate. Analysis of the green, red, and yellow fluorescence was
performed with a Bio-Rad MRC 1024 confocal microscope.
Transfections and Luciferase Assays—The coding sequences of p32
and p40 were cloned into a eukaryotic expression vector, pcDNA3.1/His
(Invitrogen). The plasmid pcDNA3.1/His-HICD, which contains the en-
tire coding sequence of p40 except for the I-mfa-like domain, was
constructed by digesting p40 cDNA cloned into pcDNA3.1/His with
EcoRV and XhoI. The resulting digest was treated with Klenow and
religated as blunt ends. This approach resulted in the deletion of the
last 101 amino acids. The Tat and Tax expression vectors, pBg312HIV-
1Lai-Tat and pSG-Tax, respectively, have been described previously
(40, 41). CEM cells were transiently cotransfected according to the
procedure published previously (42). 5 mg of pACb1 (b-galactosidase-
containing reference plasmid) was included in each transfection for
controlling the transfection efficiency. The total amount of DNA in each
transfection was the same, the balance being made up with empty
pcDNA3.1/His. Cell extracts equalized for protein content were used for
luciferase and b-galactosidase assays. For the assays with the GAL4-
binding site promoter-reporter plasmid, HIC (amino acids 120 to 355),
Tax, and Tat were fused in frame with the DNA-binding domain of
GAL4 (cloned into pBIND vector, Promega). Cotransfection assays were
performed in CEM cells in the presence of the luciferase reporter
plasmid pG5luc containing five GAL4-binding sites upstream of a min-
imal TATA box.
Immunoprecipitation and Western Blot Assays—Protein extracts
were electrophoresed onto SDS-10% polyacrylamide gel (SDS-10%
PAGE) and blotted to polyvinylidene difluoride membranes (Millipore).
The blot was then incubated overnight at 4 °C with a blocking solution
(phosphate-buffered saline containing 5% milk) prior to addition of
antiserum. After 2 h at 20 °C, the blot was washed three times with
0.5% phosphate-buffered saline/Tween 20 and incubated for 2 h with
goat anti-mouse or anti-rabbit immunoglobulin-peroxidase conjugate
(Immunotech, Marseille, France). After three washes, the membrane
was incubated with enhanced chemiluminescence (ECL) reagent (Am-
ersham Pharmacia Biotech). The membrane was then exposed for 0.5 to
5 min to hyperfilms-ECL (Amersham Pharmacia Biotech). The anti-
Xpress serum was purchased from Invitrogen and recognizes the tag
found in the Xpress leader peptide in the vector pcDNA3.1/His. The
anti-HIC serum was obtained by immunizing rabbits with purified
His6-tagged HIC polypeptide corresponding to the first 163 amino acids
of p32. HIC cDNA was cloned into the bacterial expression vector
pQE-30 (Qiagen). The N-terminal His6-tagged protein was purified as
described by the manufacturer. Immunoprecipitation assay was carried
out as described previously (43).
RESULTS
Isolation of HIC cDNA, Which Encodes a Protein Sharing
Homology with the Specific C-terminal Domain of I-mfa—Two
cDNA clones coding, respectively, for the last 60 and 153 C-
terminal amino acids of a novel protein were isolated from an
HTLV-I-infected T-cell line cDNA library (20). As the predicted
polypeptide presented homologies with the specific C-terminal
domain of I-mfa, a cellular factor known to be a bHLH repres-
sor, we decided to characterize further this novel protein. At
first, the tissue distribution of the mRNA coding for this novel
HIC protein was analyzed. All the tested lymphoid organs
(spleen, thymus, and peripheral blood leukocytes) expressed an
mRNA of about 4.4 kb (Fig. 1). This mRNA is not specific to
lymphoid tissues since it is expressed in prostate, uterus, and
small intestine. Finally, it is almost absent in testis and colon.
From these observations, we decided to screen a human spleen
cDNA library cloned into lgt11 to characterize the complete
sequence of HIC cDNA. By this approach, we were able to
isolate a 4,152-bp full-length HIC cDNA that was completely
sequenced (GenBankTM number AF054589).
Mapping of the Translation Initiation Sites—The full-length
HIC cDNA contains an open reading frame encoding a polypep-
tide of 246 amino acids if the ATG at position 591 is the
initiation codon (Fig. 2). We examined the proteins synthesized
in a cell-free system with a cDNA containing the first 1532
nucleotides of HIC sequence (the stop codon TAA is at position
1329; see Fig. 2). SDS-PAGE of the translational products
effectively revealed a protein of 32 kDa, p32, but also an unex-
pected product of 40 kDa, p40 (Fig. 3a, lane pHIC-1). To deter-
mine the origin of both polypeptides, a series of 59 truncation
mutants of pHIC-1 was generated. These experiments (Fig. 3)
demonstrated that p32 translation initiation was located be-
tween position 393 and 617 (compare the lanes pHIC-3 and
pHIC-5) suggesting that ATG at position 591 could be an ini-
tiation codon. To confirm this hypothesis, the entire region 59 to
this ATG was deleted. SDS-PAGE of the translation products
Characterization of a Novel Human I-mfa Domain-containing Protein 4849
 at CNRS on August 4, 2006 
w
w
w
.jbc.org
D
ow
nloaded from
 
synthesized from this template revealed one major protein of
32 kDa (lane pHIC-4) indicating that the first ATG effectively
is the initiation codon involved in p32 synthesis.
On the other hand, from the template pHIC-3, p40 was no
longer synthesized, whereas it was still produced from pHIC-2
(Fig. 3a). This observation suggests that the HIC cDNA clone
contains another initiation site upstream of the first ATG,
located between positions 174 and 393. There are many exam-
ples of proteins where codons other than ATG are initiation
codons (44–46). In human cells, TTG and CTG have been found
as initiation codons. To determine whether one or both CTG
located upstream of the ATG (Fig. 3b) could be translational
initiator, templates starting at positions 246 or 321, where
CTG was transformed into ATG (respectively, pHIC-I-atg and
pHIC-III-atg), were constructed. Only the ATG which starts at
position 246 generated a 40-kDa major product that could
correspond to p40 (Fig. 3a, lane pHIC-I-atg). However, when
the CTG at position 246 was mutated into a non-initiation
codon (CGG), p40 was still synthesized (Fig. 3a, lane pHIC-I-
cgg). Based on these results, it appears that both CTGs are not
initiation codons and that the initiation codon must be con-
tained within the nucleotide region between position 246 and
321. In this region, only the GTG located at position 264 be-
longs to the non-ATG codons known to be able to initiate
translation in mammalian cells. For this reason, this GTG was
mutated into ATG or CGG corresponding, respectively, to the
plasmids pHIC-II-atg and pHIC-II-cgg (Fig. 3b). From pHIC-
II-atg a 40-kDa protein was produced, whereas the synthesis of
this product was abolished with pHIC-II-cgg (Fig. 3a). This
result clearly demonstrates that the GTG at position 264 is
initiator in our cell-free system.
Taken together, our data clearly demonstrate that HIC
mRNA codes for two protein isoforms, p32 and p40, synthesized
from two different initiation codons as follows: a standard ATG
initiator for p32, and a GTG located upstream of the ATG for
p40. p32 and p40 only differ by the presence of a N-terminal
sequence containing two basic subdomains (Fig. 4a). Moreover,
their common C-terminal region shares 77% identical amino
acids with the specific C-terminal domain of I-mfa (Fig. 4b).
Localization of HIC p32 and p40 in Vivo—Next we investi-
gated the subcellular localization of both HIC protein isoforms
in vivo. COS7 cells were transfected with vectors expressing
p32 or p40 tagged with green fluorescent protein (GFP), fused
either to their N-terminal end or their C-terminal end. As
shown in Fig. 5, the position of the GFP tag apparently has no
influence on the localization of the HIC proteins. p32 is distrib-
uted primarily throughout the cytoplasm, although weak stain-
ing is detectable in the nucleus (Fig. 5, a and c). Two different
cytoplasmic patterns of p32 localization are observed, a diffuse
(Fig. 5, a and c) and a bright punctate staining (Fig. 5, b and d).
p40 also exhibits a granular distribution in the cytoplasm, but
in addition, it shows a staining pattern in the nucleus, localized
around and in the nucleoli (Fig. 5, e and f).
To be certain that the GFP tag did not influence their local-
ization, p32 and p40 were fused to a smaller tag, containing
either the myc epitope fused to their C-terminal end (Fig. 6) or
the X-press leader peptide fused to their N-terminal end (data
not shown). In COS7 cells transfected with these constructs,
p32 and p40 give the same staining pattern as that observed
with the GFP tag (compare Fig. 5 and 6). In conclusion, p32 is
FIG. 1. Tissue distribution of HIC mRNA. Northern blot of
poly(A)1 RNA from various human tissues was analyzed. Molecular
size markers in kilobases (kb) are shown on the left.
FIG. 2. The 5* end nucleotide and deduced amino acid se-
quences of the full-length HIC cDNA isolated from a human
spleen cDNA library. The amino acid sequence deduced from the
longest open reading frame is shown below the nucleotides. The se-
quence data of the complete HIC cDNA have been submitted to the
GenBankTM data base under accession number AF054589.
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predominantly cytoplasmic, whereas p40 is both cytoplasmic
and nuclear. Moreover, p32 is distributed in both a diffuse and
a punctate staining pattern throughout the cytoplasm. We do
not know why two different patterns are observed with p32.
However, preliminary data2 suggest that the I-mfa-like domain
of HIC could be involved in the formation of these cytoplasmic
granular structures.
Expression of HIC p32 and p40 in Vivo—To raise polyclonal
antibodies against HIC, rabbits were immunized with highly
purified HIC polypeptide corresponding to the first 163 amino
acids of p32. We studied the expression of HIC protein isoforms
in vivo with this antiserum by using two additional approaches.
First, we analyzed by Western blotting (Fig. 7a) protein ex-
tracts of 293T cells transfected with the eukaryotic expression
vector pcDNA3.1(2)/Myc-His containing the HIC coding se-
quence under the control of the wild type leader (from nucleo-
tide 95 to 1300, see Fig. 2). Second, we performed immunopre-
cipitation with anti-HIC from extracts of HTLV-I infected
T-cells (Fig. 7b). In both cases, a single protein was detected
with anti-HIC but not with preimmune serum (Fig. 7), the size
of this protein being consistent with the size of recombinant
p32 when expressed in eukaryotic cell lines (data not shown).
These results demonstrate that p32 is the major protein iso-
form produced from HIC mRNA in vivo.2 S. The´bault, unpublished results.
FIG. 3. Mapping of the translation
initiation sites of the HIC cDNA clone
with a cell-free system. a, all mRNAs
were translated in rabbit reticulocyte ly-
sates with either an HIC cDNA clone con-
taining the first 1532 bp or PCR-gener-
ated DNAs as templates for transcription.
[35S]Methionine and [35S]cysteine were
used in translation reactions to label pro-
teins. Translation products were ana-
lyzed by SDS-PAGE and autoradiogra-
phy. 35S-Labeled p40 and p32 are
designated by arrows. Molecular size
markers in kilodaltons are shown on the
right. The exact start of the different HIC
constructs are shown in b below the auto-
radiographs. b, nucleic acid sequence of
the 59 end of the HIC cDNA clone. The
stop codon TAG at position 171 and the
putative initiation codons are indicated in
bold. The exact position of the 59 end of
the different HIC cDNA clones is indi-
cated by an arrow. pHIC-1 and the 59
deleted plasmids, pHIC-2, -3, -4, and -5,
encode the wild type nucleotide sequence
of HIC cDNA. For the other deleted con-
structs, the 59 end was modified as fol-
lows: CTG at position 246 was trans-
formed into ATG (pHIC-I-atg) or CGG
(pHIC-I-cgg), GTG at position 264 into
ATG (pHIC-II-atg) or CGG (pHIC-II-cgg),
and CTG at position 321 into ATG
(pHIC-III-atg).
FIG. 4. The amino acid sequence of
HIC p32 and p40. a, the complete amino
acid sequence corresponds to HIC p40.
Underlined amino acids delineate both
basic rich subdomains of p40. The first
methionine of p32 corresponding to initi-
ation codon is indicated in bold. b, the
C-terminal 82 amino acids of HIC protein
aligned with the specific C-terminal do-
main of I-mfa. Identical residues are
boxed.
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p40 was not detected by both approaches suggesting that p40
is weakly expressed in vivo, probably because GTG is a poor
translation initiator. To check the existence of p40 in vivo, the
HIC coding sequence under the control of the wild type leader
(from nucleotide 95 to 1328, see Fig. 2) was cloned into the
vector pEGFP-N1, in frame with the GFP nucleotide sequence.
If both HIC isoforms are expressed in vivo, the products syn-
thesized from our construct should correspond to p40- and
p32-GFP fusion proteins, easily detectable by fluorescence mi-
croscopy. Indeed, after transfection of COS7 cells, different
patterns of staining were observed with a confocal microscope.
At first, a diffuse cytoplasmic staining (Fig. 8a) was detected
confirming that p32 is expressed in vivo from HIC cDNA. We
also found a granular staining in the cytoplasm (Fig. 8, a–c), a
pattern common to p32-GFP and p40-GFP (see Fig. 5, d and f).
Finally, staining around and in the nucleoli (Fig. 8c), similar to
the pattern described for p40-GFP (Fig. 5f), was observed. In
conclusion, taken together, our analyses demonstrate that both
p32 and p40 can be synthesized in vivo.
HIC p32 and p40 Show Opposite Effects on HTLV-I and
FIG. 5. Confocal microscopy analysis of the subcellular localization of HIC p32 and p40 with an N- or C-terminal GFP tag in vivo.
COS7 cells were transfected with 20 mg each of expression vector encoding GFP-p32 (a and b), p32-GFP (c and d), GFP-p40 (e), or p40-GFP (f). Cells
were cultivated on the glass slides and then analyzed by fluorescence 24 h after transfection. Analysis of the green, red, and yellow fluorescence
was performed with confocal microscope. The yellow color results from the merging of the green fluorescence of GFP-tagged proteins and red
staining (propidium iodide) of the cell nucleus.
FIG. 6. Confocal microscopy analysis of the subcellular localization of HIC p32 and p40 with a C-terminal myc tag in vivo. COS7
cells were transfected with 20 mg of pcDNA3.1(2)/Myc-His expressing p32 (a and b) or p40 (c) fused to the myc epitope. Microscopy analysis was
performed as described in the legend of Fig. 5.
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HIV-1 LTRs—Our results suggest that HIC protein belongs
with I-mfa to the same family of proteins that is characterized
by the presence of a specific cysteine-rich C-terminal domain.
Therefore, by analogy with I-mfa, we postulated that HIC
should be involved in gene expression regulation. Moreover, we
first isolated the HIC cDNA clone from a cDNA library of MT-2,
a T-cell line persistently infected by HTLV-I and producing
high quantity of viral particles (47). For all these reasons and
in order to try to understand the function of HIC, we investi-
gated whether HIC was able to regulate the expression of
HTLV-I LTR. For this purpose, transient cotransfection assays
were carried out using a luciferase reporter gene driven by the
HTLV-I promoter. The transfection assays were performed in
CEM cells in the presence or absence of Tax. Although Tax
alone was found to activate the expression of luciferase re-
porter gene by about 20-fold as expected, luciferase activity was
over-stimulated in the presence of p32 and p40, by 50- and
60-fold, respectively (Fig. 9). This effect is comparable to the
stimulations that have been described for cellular factors such
as CREB, CREB-2, Ets1, and TBP known to cooperate with Tax
for activating transcription from the HTLV-I LTR (20, 26, 29,
48).
By analogy with I-mfa, we postulated that the I-mfa-like
domain of HIC could be involved in this regulation. To find out
if this was indeed the case we constructed a mutated HIC p40
(HICD) deleted of its C-terminal domain. HICD has a removal
of the last 101 amino acid residues encompassing the I-mfa-like
domain (see Fig. 4). No over-stimulation of the luciferase gene
expression from the HTLV-I LTR was detected with this mu-
tant, although it was stably expressed in transfected cells (Fig.
10). This result confirms that the stimulation of luciferase
expression from HTLV-I LTR by the wild type HIC, in the
presence of Tax, is significant. Finally, to determine whether
the stimulation was specific to HTLV-I, the effects of HIC were
also tested on two other viral activators, the herpes simplex
virus transactivator VP16 and the HIV-1 Tat protein. Whereas
HIC has no effect on the VP16 activity (data not shown), the
results obtained with Tat were unexpected. In the presence of
HIC, the activation by Tat from HIV-1 LTR was down-regu-
lated, especially with p40 (Fig. 11a). Such an effect was not
detected in the presence of HICD (Fig. 11b). Taken together,
our results suggest that HIC is able to modulate the expression
of the HTLV-I and HIV-1 genomes, and its I-mfa-like domain is
involved in this effect. To define better the function of this
domain, we constructed a GAL4-HIC fusion protein in which
the GAL4 DNA-binding domain was linked in frame to HIC
(amino acids 120–355; see Fig. 4a). GAL4-HIC was assayed by
using the luciferase reporter vector pG5luc, which contains five
GAL4-binding sites upstream of a minimal TATA box. We
found that GAL4-HIC was unable to stimulate the luciferase
expression (Fig. 12a); this result suggests that HIC has no
transcriptional activation domain. On the other hand, the
GAL4-Tax and GAL4-Tat activities were stimulated 4.5- and
3-fold, respectively, in the presence of HIC (Fig. 12). Thus, HIC
has the same activator effect on both Tax and Tat when these
viral factors are positioned on the promoter.
DISCUSSION
In this report, we describe the cloning of a 4,152-bp full-
length human cDNA encoding a novel protein designated HIC.
Comparison of the nucleotide sequence of HIC cDNA with all
the sequences of EMBL and GenBankTM data bases reveals
significant homologies between the C-terminal amino acids of
HIC protein and the specific C-terminal domain of I-mfa, a
cellular factor known to inhibit the transcriptional activity of
MyoD family members and Mash2 (38, 39). By in vitro trans-
lation, we demonstrated that the HIC cDNA directed the ex-
pression of two different proteins, p32 and p40. These two
protein isoforms are synthesized from two initiation sites of
translation present in the corresponding mRNA. Site-directed
mutagenesis indicates that p32 is generated from the ATG
codon at position 591 and that p40 is an N-terminal extension
of p32 produced by alternative translation initiation at an
upstream GTG codon. Although ATG is essentially used as
initiation codon for eukaryotic mRNAs, there are several ex-
amples of cellular mRNAs where non-ATG codons located up-
stream of an ATG codon are also used as initiator for the
synthesis of protein isoforms. For instance, these include proto-
oncogenes such as c-myc, int-2, and pim-1 (49–51), as well as
the genes encoding the fibroblast growth factors (52, 53), the
Wilms’ tumor suppressor (54), and the high affinity neuroten-
sin receptor (55). However, in human cells, whereas TTG and
CTG have often been found as initiation codons, GTG has
rarely been described as initiator (56–58). Non-ATG start
codons can be used to create a functionally distinct form of the
same protein. Sometimes, extended proteins show intracellular
localizations different from their shorter counterparts (50, 59).
For HIC protein, p32 is mainly distributed throughout the
cytoplasm, whereas p40 is targeted to the nucleus. This obser-
vation can be explained by the presence in HIC p40 of an
N-terminal extension containing two clusters of basic amino
acids that could direct nuclear import (60).
Despite their different intracellular localization, p32 and p40
have similar effects on the regulation of HTLV-I and HIV-1
expression. Indeed, we found that both HIC protein isoforms
were able to stimulate the expression of a luciferase reporter
gene driven by the HTLV-I LTR promoter in the presence of
Tax but down-regulated expression from HIV-1 LTR promoter
in the presence of Tat. However, the molecular mechanism
involved in this regulation remains unclear. The effect of HIC
on Tax is obviously indirect since HIC is unable to interact
directly with Tax (data not shown). Besides, we have observed
that I-mfa is also capable of stimulating the HTLV-I transcrip-
tion in the presence of Tax,2 suggesting that the C-terminal
cysteine-rich domain, common to both proteins, is involved in
this regulation. Abolishment of HIC activity by deleting its
I-mfa-like domain confirms this hypothesis. The I-mfa-specific
cysteine-rich domain is required for binding to some bHLH
factors (38). This interaction masks the nuclear localization
signal of the transcriptional factor and thus retains the bHLH
in the cytoplasm. It is unlikely that such a similar mechanism
is involved in retroviral promoter regulation by HIC in T-cells.
The bHLH proteins have not been described as regulators of
FIG. 7. Detection of p32 in vivo by Western blot (a) or by im-
munoprecipitation (b). a, 100 mg of total protein extracts were ana-
lyzed by SDS-PAGE and immunoblotting using control serum obtained
from an uninjected rabbit (lanes 1 and 2) or anti-HIC serum (lanes 3
and 4). Protein extracts were prepared from 293T cells transfected with
empty pcDNA3.1(2)/Myc-His (lanes 1 and 3) or with pcDNA3.1(2)/Myc-His
containing the HIC coding sequence under the control of the wild type leader
(lanes 2 and 4). b, HIC p32 was immunoprecipitated from MT-2 cell lysate
(20 3 106 cells) using control serum (lane 1) or anti-HIC serum (lane 2) and
protein A-Sepharose. Precipitates were analyzed by SDS-PAGE and immu-
noblotting with anti-HIC serum. The predicted positions of p40 and p32 are
designated by arrows on the right of the immunoblots.
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the HIV-1 and HTLV-I transcription. On the other hand, Tax is
known to repress the activity of bHLH factors (61–63), proba-
bly through competition for common transcriptional regulators
as described recently for another transcriptional factor, c-Myb.
Tax antagonizes the c-Myb transcriptional activity by compet-
ing for CBP (64). In our model system, HIC protein could
stimulate the transcription of the HTLV-I LTR promoter by
preventing the interaction of bHLH proteins with transcrip-
tional regulators such as CBP which, in turn, would bind to
Tax. This hypothesis could also explain why HIC protein is able
to stimulate Tat activity when this viral factor is positioned on
the HIV-1 LTR promoter since Tat is also known to recruit
transcriptional regulators to the viral promoter (65–67). On
the other hand, the down-regulating effect of HIC on Tat un-
bound to the viral promoter still remains unclear. A direct
interaction between HIC and Tat could be involved in such a
negative effect on Tat especially since both proteins localize to
the nucleolus (68). Experiments are under way to evaluate
further this possibility.
Another intriguing question is the putative involvement of
CD4 in the control of HIC activity. Indeed, we have previously
reported that monoclonal antibodies directed against the Ig
CDR3-like region in the extracellular domain 1 of CD4 can
inhibit HIV-1 transcription in the MT-2 T-cell line superin-
fected by this virus, by inducing signals that repress NF-kB
activation (43, 69). We have established that the transcription
of the lck gene, which encodes a cytoplasmic CD4-associated
kinase linking CD4 to signal transduction cascade, is repressed
in MT-2 cells (43, 69). This result suggests that inhibition of
HIV-1 transcription in these cells is a consequence of signal
transduction probably mediated by an unidentified factor ca-
pable of associating with CD4. It is noteworthy that several
reports demonstrate that some CD4 signals do not require Lck
thereby suggesting the involvement of unknown molecules
(70–72). In trying to identify this factor by the yeast two-hybrid
approach by using the CD4 cytoplasmic tail as a bait, we
isolated two cDNA clones encoding the C-terminal domain of
HIC. We have also found by two-hybrid assay that HIC binds
more efficiently to the wild type CD4 cytoplasmic tail than to a
mutant form with cysteine mutations in its cytoplasmic frag-
ment, suggesting that cysteines of HIC and CD4 are likely
involved in the protein-protein interaction.3 Interestingly, HIC
is capable of down-regulating HIV-1 transcription. However,
confocal microscopy analyses do not argue in favor of CD4/HIC
cellular colocalization. Moreover, we also failed to coimmuno-
precipitate HIC and CD4 from cotransfected cells. For these
reasons, we cannot presently claim that the interaction be-
tween HIC and CD4 really occurs in MT-2 cells. Yet, we can
expect that further characterization of exact mechanisms in-
volved in the regulation of HTLV-I and HIV-1 LTR expression
by HIC may contribute to answer this question.
Our results suggest that p32 is the main isoform of HIC
protein in HTLV-I-infected T-cells. p32 presents many similar-
3 N. Coudronnie`re and J.-M. Mesnard, unpublished results.
FIG. 9. Stimulation of HTLV-I LTR by HIC p32 and p40. CEM
cells were cotransfected with 2 mg of HTLV-I LTR-luciferase, 5 mg of
pACb1 (b-galactosidase-containing reference plasmid), 1 mg of Tax ex-
pression vector pSG-Tax or empty pSG-5 vector, and 0, 2, or 10 mg of
pcDNA3.1/His expressing p32 or p40. Luciferase values were normal-
ized for b-galactosidase activity and are expressed as fold increase
relative to that of cells transfected with 2 mg of HTLV-I LTR-luciferase,
5 mg of pACb1, 1 mg of pSG-5, and 10 mg of empty pcDNA3.1/His. Values
are the means 6 S.D. (n 5 3).
FIG. 8. Analysis of HIC expression in vivo from the wild type HIC cDNA by confocal microscopy. COS7 cells were transfected with
pEGFP-N1 containing GFP nucleotide sequence in frame with the HIC coding sequence under the control of the wild type leader. Analysis of
transfected cells was carried out as described in the legend of the Fig. 5. The three different patterns, which have been observed, are shown in a–c.
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ities with I-mfa as follows: (i) their translation is initiated at an
ATG codon, (ii) their C-terminal region shares 77% identical
amino acids, (iii) p32 and I-mfa have the same size, 246 amino
acids in length, (iv) both p32 and I-mfa are mainly located in
the cytoplasm, (v) p32 and I-mfa are involved in gene expres-
sion regulation, and (vi) their C-terminal domain is indispen-
sable to this function. On the other hand, p40 seems to be
weakly expressed in HTLV-I-infected T-cells. However, several
observations suggest that p40 could also play a major role in
vivo. At first, the 59 structure of HIC mRNA is completely
different from that of I-mfa mRNA. Whereas the ATG initiation
codon of I-mfa cDNA is located at position 150, the ATG initi-
ator of p32 is located at position 591 of HIC cDNA. Such a very
long leader is rare for eukaryotic mRNAs and suggests that the
regulation of HIC protein expression in vivo is more complex
than that of I-mfa. Second, preliminary data2 indicate that the
N-terminal domain of p40 is involved in the import of HIC in
the nucleus, showing that this domain has an essential func-
tion in vivo. Finally, p40 is more efficient than p32 in regulat-
ing the expression of a luciferase gene driven by the HTLV-I or
HIV-1 LTR.
In conclusion, we propose that HIC and I-mfa represent two
members of a new family of gene expression regulators, char-
FIG. 10. The I-mfa-like domain of HIC is involved in the stim-
ulation of the HTLV-I LTR expression. a, CEM cells were cotrans-
fected with 2 mg of HTLV-I LTR-luciferase, 5 mg of pACb1, 1 mg of
pSG-Tax or empty pSG-5, and 10 mg of empty pcDNA3.1/His or 10 mg of
pcDNA3.1/His expressing HIC p40 or HICD. Values are the means 6
S.D. (n 5 3). b, expression of the wild type and mutated HIC proteins in
cotransfected CEM cells was checked by Western blotting by using the
anti-Xpress serum: 2, cells cotransfected with empty pcDNA3.1/His;
p40, cells cotransfected with pcDNA3.1/His expressing HIC p40; HICD,
cells cotransfected with pcDNA3.1/His expressing HICD.
FIG. 11. Down-regulation of HIV-1 LTR by HIC p32 and p40. To
test the effects of HIC p32 and p40 (a) and HICD (b) on the HIV-1
LTR-luciferase, CEM cells were transfected as described in the legends
of Fig. 9 and 10, but with HIV-1 LTR and Tat expression vector instead
of HTLV-I LTR and pSG-Tax. Values are the means 6 S.D. (n 5 3).
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acterized by a particular cysteine-rich C-terminal domain. Our
study opens a new perspective in understanding the role of
these new factors in the pathology of diseases such as AIDS and
T-cell leukemia.
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